3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms
2
Colorectal Neoplasms
2
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Leiomyosarcoma
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Islet Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Carcinoid Tumor
1
Breast Neoplasms
1
Interventions
Bevacizumab
27
Leucovorin
23
Fluorouracil
22
Oxaliplatin
17
Irinotecan
15
Cetuximab
14
pembrolizumab
11
IFL protocol
11
Panitumumab
10
Folfox protocol
10
Capecitabine
10
Gemcitabine
7
adagrasib
5
Cisplatin
5
Carboplatin
5
Ramucirumab
4
Colonoscopy
4
veliparib
3
spartalizumab
3
selpercatinib
3
regorafenib
3
labetuzumab
3
durvalumab
3
conatumumab
3
cemiplimab
3
Pemetrexed
3
Paclitaxel
3
HMPL-013
3
Drug Therapy
3
5,11-methenyltetrahydrohomofolate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colonic Neoplasms
×
cixutumumab
×
Clear all
NCT00845039
2018-07-02
FC-4
Eli Lilly and Company
Phase 2
Terminated
4 enrolled
9 charts